Navigation Links
Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
Date:2/10/2009

assessment panel that was blinded to the treatment assignments.

The most common serious toxicities (>5%) seen in previous trials of pixantrone include grade 3 and 4 neutropenia and febrile neutropenia. Complete safety information is not yet available for the study, however, the study was monitored on an ongoing basis by an independent Data Safety Monitoring Committee and no serious concerns were raised.

The study received Special Protocol Assessment approval from the U.S. Food and Drug Administration (FDA) in 2004 and pixantrone has received fast track designation for this indication.

About Pixantrone

Pixantrone (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scientists in Bresso, Italy. Pixantrone is a novel DNA major groove binder that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. Anthracyclines have been shown to be very active clinically in a number of tumor types, such as lymphoma, leukemia, and breast cancer. For these diseases, anthracycline-containing chemotherapy regimens are effective in first-line (initial) treatment. However, they may cause cumulative heart damage that limits lifetime dosage and does not allow for retreatment. Pixantrone has been designed to reduce the potential for heart damage compared to currently available anthracyclines or anthracenediones without a loss in anti-tumor or immunomodulatory activities.

About IDIS

IDIS is the world leader in the development and implementation of named patient programs and has a proven track record of working in strategic partnership with US-based companies to bring new drugs to Europe for the first time. IDIS supports customers in over 100 countries, supplying more than 400 different medicines per m
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
2. PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
3. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
4. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
5. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
6. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
7. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
8. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
11. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... KING OF PRUSSIA, Pa. , Feb. 27, 2015 ... part of its ongoing commitment to the global bleeding ... it is donating 2 million international units (IUs) of ... WFH is an international not-for- profit organization which has ... and other inherited bleeding disorders. The donation supports the ...
(Date:2/27/2015)... TEL-AVIV, Israel , February 27, 2015 ... Unternehmen baut sein bahnbrechendes Überwachungssystem für kongestive ... weiter aus -   ... Medical Technologies, die ein neuartiges Herzüberwachungssystem für ... gab heute bekannt, dass sie ein Finanzierungsvorhaben ...
(Date:2/27/2015)... 2015  Two mass spectrometry technologies MALDI ... their effectiveness is established, according to biotechnology ... says that while mass spectrometry (mass spec ... in proteomic biomarker discovery and validation, mass ... techniques has struggled to elucidate molecular distribution ...
Breaking Medicine Technology:CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 3Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3
... Mich., Jan. 23, 2012  Researchers at the University of ... and found that less expensive, more effective tests are ... of patients receiving neuropathy diagnoses undergo high-cost, low-yield MRIs ... according to the study that will be published Jan. ...
... FALLS, N.Y., Jan. 23, 2012  Niagara Thermal Products LLC ... & Sons, Inc. The acquisition brings together two highly ... value custom thermal solutions in the aerospace, defense and ... ) "The addition of Kittredge,s industry recognized ...
Cached Medicine Technology:Neuropathy Patients More Likely to Receive High-cost, Low-yield Screening Instead of More Effective Tests 2Neuropathy Patients More Likely to Receive High-cost, Low-yield Screening Instead of More Effective Tests 3Niagara Thermal Products LLC Announces the Acquisition of J. Kittredge & Sons, Inc. 2Niagara Thermal Products LLC Announces the Acquisition of J. Kittredge & Sons, Inc. 3
(Date:2/28/2015)... February 28, 2015 The noted Friedman ... that they have officially relaunched their website. The new ... but it contains a new section about their team ... read the full biographies of each Friedman Dental Group ... the website was designed to provide our patients with ...
(Date:2/28/2015)... Javon Bea Mercy Health System CEO ... stroke capable by the State of Illinois, enabling potential ... Harvard Hospital. , The hospital was required to submit ... treat stroke according to national standards of care for ... to bypass hospitals not designated as an Emergent Stroke ...
(Date:2/28/2015)... Memphis, TN: MedixSafe has retracted a previous ... security reader named Guardian 2. The correct product ... biometric scanner that significantly increases the complexity of ... biometric scanner provides fast and easy access for ... narcotics lockers with Vanguard technology tracks inventory ...
(Date:2/28/2015)... 28, 2015 1Heart Caregiver Services ... emerging brand at Houston Texas Franchise Expo South ... sending its executive delegates headed by Vice-President of ... and Training Randolph Clarito. , Franchise Expo South, ... last February 4-7 and featured Franchise brands of ...
(Date:2/27/2015)... 27, 2015 OnChip Devices , ... introduced miniature, wire bondable, silicon ESD (Electrostatic Discharge) protection ... The ESD88NP and ESD88PN ... sensitive LED and IC products. These Zeners exhibit ... All devices meet the requirements of IEC61000 and ...
Breaking Medicine News(10 mins):Health News:Friedman Dental Group Announces Their Updated Website 2Health News:Mercy Harvard Hospital Recognized as Leader in Stroke Care - Javon Bea 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 3Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 3
... a neurobiological side to it. A new study suggests ... ,David Erritzoe and his colleagues at Copenhagen University ... normal weight and 29 overweight people. They found that ... the neurotransmitter serotonin than those of normal weight, reported ...
... methods of treatment in Urogynaecology will be the focus ... on Urogynaecology and Reconstructive pelvic surgery, that begins here ... of a pelvic surgery, being conducted at Government Kasturba ... ,,Briefing reporters about the three-day conference, Dr ...
... emirate will start a health insurance policy next month which ... companies that fall under the Phase 1 category will be ... which will make the lowest paid the first to benefit ... of the General Authority for Health Services (GAHS) in Abu ...
... has come up in Kolkata to contain Diarrheal diseases in ... one of the best of its kind equipped with the ... Minister for Health & Family Welfare, Dr. Anbumani Ramadoss, will ... named the 'Diarrheal Research and Control Centre' (DRCC) in the ...
... to Dr. Alexis Carrel digestive wastes which become stagnant in our ... 1911 for his discovery that growing live tissue cells can be ... not removed for three days then the cells become weak and ... meal that one eats. ,Studies have shown that if ...
... NHS news it is said that the breast cancer drug Herceptin ... But this is not happy news to the grieving family of ... cancer. But NHS officials denied her the drug which led to ... ,By profession she was an advertising art director from Wimbledon, ...
Cached Medicine News:Health News:Health Minister Inaugurates Institute for Diarrhea Diseases 2
Auto Refkeratomoeter...
... Management System answers the day-to-day needs ... flexibility. From programming to data retrieval, ... management right where you want it. ... to help each patient become ambulatory ...
... can be customized with selectable performance parameters ... and therapies. The COLLEAGUE pumps allow ... used for both gravity and pump regulation, ... simple infusions to medication therapies requiring complex ...
ChildLab is a service of Children's Hospital, Columbus Ohio...
Medicine Products: